A miR-361-5p/ ORC6/ PLK1 axis regulates prostate cancer progression
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.High ORC6 levels correlate with poor prostate cancer (PCa) prognosis. Targeting the miR-361-5p/ORC6/PLK1 pathway shows potential for PCa treatment.
Area Of Science
- Oncology
- Molecular Biology
- Genetics
Background
- Prostate cancer (PCa) is a leading malignancy, with metastatic progression significantly impacting patient outcomes.
- Understanding PCa development mechanisms is crucial for improving patient prognosis and therapeutic strategies.
Purpose Of The Study
- To investigate the expression and functional role of ORC6 in prostate cancer progression.
- To elucidate the molecular mechanisms underlying ORC6's function in PCa.
Main Methods
- Analysis of ORC6 expression in PCa tissues.
- In vivo and in vitro functional experiments (e.g., knockdown studies).
- RNA sequencing (RNA-seq), RNA immunoprecipitation (RIP), and luciferase reporter assays.
Main Results
- ORC6 expression is elevated in advanced PCa and associated with poor prognosis.
- ORC6 knockdown inhibits PCa cell proliferation, growth, and migration.
- ORC6 promotes PLK1 expression and is regulated by miR-361-5p and E2F1.
Conclusions
- The miR-361-5p/ORC6/PLK1 axis represents a novel regulatory pathway in prostate cancer.
- Targeting this axis offers a potential therapeutic strategy for PCa patients.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Three of the best-understood negative regulators are p53, p21, and retinoblastoma protein (Rb). The regulatory roles of each of these proteins were discovered after faulty copies were found in cells with uncontrolled replication (i.e.,...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...